Stifel lowered the firm’s price target on Inspire Medical (INSP) to $85 from $95 and keeps a Buy rating on the shares. The firm acknowledges near-term uncertainty and moved its 2026 estimates slightly below the low-end of management’s recently revised guidance, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical jumps after KeyBanc says CMS ‘appears ready’ to add C-codes
- Inspire Medical halted again for volatility after jumping 34% to $79.11
- Inspire Medical Systems trading resumes
- Inspire Medical jumps after KeyBanc note on CMS codes
- Inspire Medical Systems trading halted, volatility trading pause